Drug intelligence / Profile preview

NMC-001

Development stage: Preclinical
Lead developer: NomoCan Pharmaceuticals
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Vaccines & Immunotherapeutics, Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

NMC-001 is a human IgG1 monoclonal antibody that targets MDM2, a protein known to negatively regulate the tumor suppressor p53. By inhibiting MDM2, NMC-001 may restore or enhance p53 activity, leading to increased tumor cell apoptosis and growth inhibition. The drug is being developed primarily for pancreatic cancer and is currently in preclinical development. The originator and developer of this drug is Nomocan Pharmaceuticals[1][2].

Other names: NMC 001NMC001NMC-001

Targets

MDM2 (Mouse double minute 2 homolog)

Beyond the preview

Go deeper on NMC-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NMC-001.

Explore the full profile